473 related articles for article (PubMed ID: 33004159)
1. Use of cannabidiol (CBD) for the treatment of chronic pain.
Urits I; Gress K; Charipova K; Habib K; Lee D; Lee C; Jung JW; Kassem H; Cornett E; Paladini A; Varrassi G; Kaye AD; Viswanath O
Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):463-477. PubMed ID: 33004159
[TBL] [Abstract][Full Text] [Related]
2. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
3. The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence.
Boyaji S; Merkow J; Elman RNM; Kaye AD; Yong RJ; Urman RD
Curr Pain Headache Rep; 2020 Jan; 24(2):4. PubMed ID: 31980957
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
5. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
[TBL] [Abstract][Full Text] [Related]
6. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
7. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
8. Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model.
Eeswara A; Pacheco-Spiewak A; Jergova S; Sagen J
PLoS One; 2023; 18(3):e0282920. PubMed ID: 36913400
[TBL] [Abstract][Full Text] [Related]
9. Effect of combined doses of Δ
Rock EM; Sullivan MT; Pravato S; Pratt M; Limebeer CL; Parker LA
Psychopharmacology (Berl); 2020 Mar; 237(3):901-914. PubMed ID: 31897571
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol and Delta-9-Tetrahydrocannabinol Interactions in Male and Female Rats With Persistent Inflammatory Pain.
Britch SC; Craft RM
J Pain; 2023 Jan; 24(1):98-111. PubMed ID: 36122809
[TBL] [Abstract][Full Text] [Related]
11. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
12. [Nabiximols as a substitute for cannabis].
Dumont GJH
Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33201625
[TBL] [Abstract][Full Text] [Related]
13. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
14. Cannabis constituent synergy in a mouse neuropathic pain model.
Casey SL; Atwal N; Vaughan CW
Pain; 2017 Dec; 158(12):2452-2460. PubMed ID: 28885457
[TBL] [Abstract][Full Text] [Related]
15. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol modulation of antinociceptive tolerance to Δ
Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM
Psychopharmacology (Berl); 2018 Nov; 235(11):3289-3302. PubMed ID: 30238130
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
18. Effects of Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys.
Carey LM; Maguire DR; France CP
Drug Alcohol Depend; 2023 Mar; 244():109787. PubMed ID: 36753805
[TBL] [Abstract][Full Text] [Related]
19. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
